- Home
- ONCY vs DYAI Comparison
ONCY vs DYAI Comparison
Compare ONCY & DYAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONCY
- DYAI
- Stock Information
- Founded
- ONCY 1998
- DYAI 1979
- Country
- ONCY Canada
- DYAI United States
- Employees
- ONCY N/A
- DYAI N/A
- Industry
- ONCY Pharmaceuticals and Biotechnology
- DYAI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ONCY Health Care
- DYAI Health Care
- Exchange
- ONCY Nasdaq
- DYAI Nasdaq
- Market Cap
- ONCY 53.6M
- DYAI 54.4M
- IPO Year
- ONCY 1999
- DYAI 2004
- Fundamental
- Price
- ONCY $0.56
- DYAI $1.35
- Analyst Decision
- ONCY Strong Buy
- DYAI Strong Buy
- Analyst Count
- ONCY 4
- DYAI 1
- Target Price
- ONCY $4.00
- DYAI $6.00
- AVG Volume (30 Days)
- ONCY 224.8K
- DYAI 60.6K
- Earning Date
- ONCY 03-07-2025
- DYAI 03-26-2025
- Dividend Yield
- ONCY N/A
- DYAI N/A
- EPS Growth
- ONCY N/A
- DYAI N/A
- EPS
- ONCY N/A
- DYAI N/A
- Revenue
- ONCY N/A
- DYAI $3,495,389.00
- Revenue This Year
- ONCY N/A
- DYAI $51.30
- Revenue Next Year
- ONCY N/A
- DYAI $73.26
- P/E Ratio
- ONCY N/A
- DYAI N/A
- Revenue Growth
- ONCY N/A
- DYAI 20.58
- 52 Week Low
- ONCY $0.55
- DYAI $0.93
- 52 Week High
- ONCY $1.53
- DYAI $2.67
- Technical
- Relative Strength Index (RSI)
- ONCY 27.91
- DYAI 42.96
- Support Level
- ONCY $0.58
- DYAI $1.29
- Resistance Level
- ONCY $0.65
- DYAI $1.45
- Average True Range (ATR)
- ONCY 0.03
- DYAI 0.10
- MACD
- ONCY -0.00
- DYAI -0.00
- Stochastic Oscillator
- ONCY 1.34
- DYAI 31.03
About ONCY Oncolytics Biotech Inc.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.
About DYAI Dyadic International Inc.
Dyadic International Inc is a world-wide biotechnology platform company. The company has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins, and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.